Advertisement
Advertisement
OBIO
Orchestra BioMed Holdings, Inc. Ordinary Shares
5.73
USDSponsored
+0.03
+0.53%
Nov 10, 15:59 UTC -5
Closed
After-Market
5.76
+0.03
+0.61%
Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) Earnings
OBIO Earnings Reports
Positive Surprise Ratio
OBIO beat 12 of 14 last estimates.
86%
Next Report
Next Week
Date of Next Report
Nov 16, 2026
Estimate for Q3 26 (Revenue/ EPS)
$108.12K
/-$0.40
Implied change from Q2 26 (Revenue/ EPS)
+22.86%
/+5.26%
Implied change from Q3 25 (Revenue/ EPS)
-87.44%
/--
Orchestra BioMed Holdings, Inc. Ordinary Shares earnings per share and revenue
On Aug 10, 2026, OBIO reported earnings of -0.38 USD per share (EPS) for Q2 26, beating the estimate of -0.39 USD, resulting in a 4.95% surprise. Revenue reached 88.00 thousand, compared to an expected 123.83 thousand, with a -28.93% difference. The market reacted with a -1.35% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.40 USD, with revenue projected to reach 108.12 thousand USD, implying an increase of 5.26% EPS, and increase of 22.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Orchestra BioMed Holdings, Inc. Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Orchestra BioMed Holdings, Inc. Ordinary Shares reported EPS of -$0.38, beating estimates by 4.95%, and revenue of $88.00K, -28.93% below expectations.
How did the market react to Orchestra BioMed Holdings, Inc. Ordinary Shares's Q2 2026 earnings?
The stock price moved down -1.35%, changed from $4.46 before the earnings release to $4.40 the day after.
When is Orchestra BioMed Holdings, Inc. Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 16, 2026.
What are the forecasts for Orchestra BioMed Holdings, Inc. Ordinary Shares's next earnings report?
Based on --
analysts, Orchestra BioMed Holdings, Inc. Ordinary Shares is expected to report EPS of -$0.40 and revenue of $108.12K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.